The content on this website is only for individuals that have been prescribed NEXTSTELLIS in Australia.

icon-pt-brochure-upd
NEXTSTELLIS Brochure
Download NEXTSTELLIS Brochure
resource-icon-upd - pnk
Frequently Asked Questions
Go to FAQs
pt-info-card
Information Card for Women
Download Info Card

The following content is for Australian patients who have been prescribed this product. To access the content, please insert only the numbers that appear after the letters AUST R as printed on the product's pack

AUST R

Dosing

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

IMPORTANT SAFETY INFORMATION FOR NEXTSTELLIS® (estetrol/drospirenone tablets) 

▼  This medicine is new and is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience to your doctor, or directly at www.tga.gov.au/reporting-problems

References

1. Gemzell-Danielsson K, et al. Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022; 129: 63-71. 2. NEXTSTELLIS Product Information. 3. NEXTSTELLIS Consumer Medicine Information. 4. Stanczyk FZ, et al. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706-727.

NEXTSTELLIS is a registered trademark used under license.All other brands are trademarks of their respective owners.© 2022 Mayne Pharma International Pty Ltd Main North Rd Salisbury South, SA. 5106
All rights reserved.NEX0015 Aug 2022
  Back to Top